Pazopanib Hydrochloride

Louisville, Kentucky-based US WorldMeds has received full US FDA approval for Tecelra (afamitresgene autoleucel), the TCR-T cell therapy originally developed by Adaptimmune and acquired by US WorldMeds in 2025. The FDA gave the nod to convert the therapy’s August 2024 accelerated approval and expand its label to include pediatric patients as young as 12 years old with unresectable or metastatic synovial sarcoma. The decision is notable on two counts: it converts the first engineered T-cell therapy ever approved for a solid tumor from accelerated to full status, and it extends that access to adolescents — a population in which synovial sarcoma disproportionately occurs and for which systemic options have been limited. Tecelra is indicated for patients who have received prior chemotherapy, carry specific HLA alleles (HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P), and whose tumors express the MAGE-A4 antigen confirmed by an FDA-approved or cleared companion diagnostic. Administered as a single infusion, the therapy requires inpatient monitoring for at least seven days post-infusion, with patients advised to remain near a healthcare facility for two weeks. A boxed warning is included in the prescribing information. The full approval was supported by data from SPEARHEAD-1 (Cohorts 1, 2, and 3), an open-label, single-arm Phase II study enrolling 137 patients. The primary efficacy outcome was overall response rate (ORR) as determined by independent review. Tecelra demonstrated an ORR of 43.8%, with a complete response rate of 3.6%. Median duration of response was 5.3 months (95% CI: 4.5–8.2), and 31.9% of responding patients maintained a response for 24 months or longer. Tecelra is a genetically modified autologous T-cell therapy engineered to express an affinity-enhanced T-cell receptor (TCR) targeting MAGE-A4, a cancer-testis antigen expressed in synovial sarcoma but largely absent from normal adult tissue. Unlike CAR-T approaches, which recognize surface proteins, the TCR-based mechanism allows targeting of intracellular antigens presented via HLA molecules — the basis for the companion HLA-typing requirement. In the absence of a dedicated approved systemic therapy for synovial sarcoma specifically, the practical comparators in the post-chemotherapy setting are agents approved for broader soft tissue sarcoma populations. Pazopanib (Votrient), approved by the FDA in 2012 for previously treated advanced soft tissue sarcoma, and trabectedin (Yondelis), approved in 2015 for liposarcoma and leiomyosarcoma, are both used in this patient population — neither carries a synovial sarcoma-specific label, and neither is biomarker-restricted. Tecelra’s eligibility criteria, while narrowing the treatable population, define a molecularly selected group in which the 43.8% ORR represents a clinically meaningful signal relative to available alternatives. US WorldMeds acquired Tecelra and the broader Adaptimmune cell-therapy portfolio in August 2025 for USD 55 million upfront, with up to USD 30 million in additional milestone payments. The full approval and pediatric label expansion represent the first major regulatory milestone under that ownership. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.